Fresenius Medical Care announced today that it will invest $25 million in Humacyte in connection with the merger of Humacyte and a SPAC. Humacyte, which develops implantable human acellular vessels for multiple vascular repair, reconstruction and replacement, entered into a merger with a special purpose acquisition company (SPAC), leading Fresenius to increase its position in […]
Mergers & Acquisitions
Bioventus triggers $50M option to acquire CartiHeal
Bioventus (NSDQ:BVS) announced today that it chose to make a $50 million escrow payment to acquire CartiHeal and its Agili-C implant. Durham, N.C.-based Bioventus elected to make its escrow payment pursuant to its option and equity purchase agreement with CartiHeal to signal its intent to move forward with an acquisition of the company. According to […]
Hillrom stock skyrockets amid reports that Baxter is close to acquisition
Baxter (NYSE:BAX) is reportedly in advanced talks to acquire Hillrom (NYSE:HRC) for approximately $10 billion. The Wall Street Journal reported yesterday that the talks were ongoing at an advanced stage. WSH previously reported on rumblings of a potential deal last month. Hillrom’s stock shot up when that report came out, and it’s rising again today, […]
MedTech 100 roundup: Industry reaches another high point
The medtech industry is continuing its massive 2021 boom, with the past week marking yet another record in the markets. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week (Aug. 27) at 121.05 points, representing a 1.2% rise from the 119.63-point mark set a week before. […]
EU to investigate Illumina’s decision to close $8B Grail acquisition
The European Commission announced that it opened an investigation to assess Illumina’s (NSDQ:ILMN) recently completed acquisition of Grail. Last week, Illumina completed its long-awaited, highly-scrutinized acquisition of the cancer detection company that spun out from Illumina nearly five years ago. The $8 billion acquisition was initially announced in September 2020. Within the announcement of the […]
MedTech 100 roundup: On the rise again
After a slight hiccup disrupted weeks of improvement, the medtech industry again flexed its muscles over the last seven days. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week (Aug. 20) at 119.63 points, representing a 1.5% rise from the 117.92-point tally set a week prior. […]
Illumina completes $8B Grail acquisition, companies remain separate amid European review
Illumina (NSDQ:ILMN) announced that it completed its long-awaited and much-scrutinized acquisition of cancer detection company Grail. Illumina, however, also said in a news release that it will hold Grail as a separate company as the European Commission conducts an ongoing regulatory review. A decision from the EU regulators is projected after the deal expires, but […]
Strata Skin Sciences buys Ra Medical’s Pharos dermatology business
Strata Skin Sciences (NSDQ:SSKN) announced that it acquired the Pharos dermatology business from Ra Medical (NYSE:RMED). Horsham, Pa.-based Strata can now market its full business solution to Ra Medical’s existing customer base comprised of 400 dermatology practices, offering opportunities to increase its recurring revenue base and a pathway to gain additional placements for its XTRAC […]
MedTech 100 roundup: Hot streak comes to slight halt
After several weeks of high-level performance, the medtech industry saw its first dip in a while over the last seven days. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week (Aug. 13) at 117.92 points, marking a –1.2% dip from the 119.41-point tally a week prior […]
Memic Innovative Surgery to go public via SPAC merger
Memic Innovative Surgery announced that it entered into a merger agreement with special purpose acquisition company MedTech Acquisition Corp. Tel Aviv, Israel-based Memic will operate under its current name upon the closing of the transaction, with Dr. Maurice R. Ferré — an independent director of MedTech and current chairman of Memic — will serve as […]
Cigarette maker Philip Morris acquires another inhaled therapeutic company
Philip Morris (NYSE:PM) announced today that it acquired OtiTopic and its late-stage inhalable acetylsalicylic acid (ASA) treatment. Los Angeles-based OtiTopic develops the Asprihale patented dry powder inhalation ASA treatment to treat acute myocardial infarction as a self-administered aerosol. Get the full story at our sister site, Drug Delivery Business News.
